Community vital signs (CVS): an integrated community-based approach to identify undiagnosed hypertension in nigeria

Ended Project Grant Awarded Last action

Award ID
R61HL172240
Recipient
Awarding agency
Obligated
$615,948

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Place of performance
Oregon, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Hypertension (HTN) is a leading modifiable risk factor for global cardiovascular disease and stroke morbidity and mortality. Nigeria, africa's most populous country, has a high HTN burden. Evidence-based interventions (EBIS) for detection and initiation of treatment for HTN are not widely implemented in nigeria. These EBIS include widely available (1) BP screening (reaching all adults >18 years of age) to identify HTN early and (2) connections to ongoing primary care for HTN management. In partnership with community and clinical stakeholders, we are currently adapting community-based strategies shown to be effective in increasing HIV screening and connections to care. The proposed adapted strategies - called community vital signs (CVS) strategies - will utilize community-based screenings, digital technologies, and supportive approaches to connect people to healthcare facilities, leveraging our practice-based research network of community clinics within the model innovation research centers created by the nigeria implementation science alliance. We will use the RE-aim (reach, effectiveness, adoption, implementation, maintenance) and epis (exploratory, preparation, implementation, sustainment) implementation science frameworks to guide our work. Aim 1 / R61 phase (year 1): engage stakeholders to refine and finalize the CO-creation of CVS strategies aiming to increase rates of BP screening and connections to care in nigeria. By the end of the R61 phase, we will have final CVS strategies and will recruit, train, and conduct implementation readiness assessments at 12 community-based sites connected with 12 healthcare facilities in 12 nigerian cities (2 in each of nigeria's 6 regions). R33 phase (years 2-5) aim 2: implement and assess CVS strategies aiming to increase rates of BP screening at all 12 study sites (N=24,000 participants). We will initiate quarterly, community-based BP screenings and evaluate using RE-aim. Aim 3: implement and compare 2 different CVS strategies to make connections to primary care for those found to have high BP readings that meet HTN criteria at all study sites. We will conduct a nested, hybrid implementation-effectiveness type III trial using a parallel 2-arm cluster randomized design. Arm a (6 sites, N~3,000 participants): support connection to primary care by utilizing mhealth digital technologies with bidirectional sharing of BP data between community screening site and primary care clinic, coupled with a voucher for a medication starter kit (core strategies); arm B (6 sites, N~3,000 participants): core strategies plus community health navigators making handoffs to clinic and sending text messages (core+ strategies). This project promotes equitable access to HTN diagnosis and connections to care, especially in cities where HTN prevalence is highest. IT has the potential to significantly increase rates of early HTN detection and prevent the morbidity and mortality associated with the downstream effect of undiagnosed and uncontrolled HTN. IT will provide evidence for scale-up of interventions to support self- management of non-communicable chronic diseases in nigeria and other low- and middle-income countries.

Transactions

Action Obligated Date
Amendment -$17,807
Original award $633,755

Subawards

Subrecipient Amount Awarded
University Of Nigeria Nsukka Community Vital Signs (CVS): An integrated community-based approach to identify undiagnosed hypertension in Nigeria $384,474
Kaiser Foundation Hospitals $55,354

Quick answers

Who received award R61HL172240?

R61HL172240 was awarded to Oregon Health & Science University by National Heart Lung and Blood Institute (National Institutes of Health) on March 1, 2024.

How much is award R61HL172240 worth?

$615,948 has been obligated on R61HL172240.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login